BOULDER, Colo.--(BUSINESS WIRE)--April 23, 2007--Array BioPharma
Inc. (NASDAQ: ARRY) announced today that it intends to offer to sell,
subject to market and other conditions, 7,000,000 shares of its common
stock in an underwritten public offering. The Company intends to grant
the underwriters a 30-day option to purchase up to an additional
1,050,000 shares of its common stock to cover over-allotments. All of
the shares are being offered by the Company.
J.P. Morgan Securities Inc. and Banc of America Securities LLC are
acting as joint book-running managers of the offering. Jefferies &
Company, Inc. and Piper Jaffray & Co. are acting as co-managers of the
offering. Information about the offering is available in the
prospectus supplement for the offering filed with the Securities and
Exchange Commission. Copies of the prospectus supplement can be
obtained from J.P. Morgan's prospectus department at 4 Chase Metrotech
Center, CS Level, Brooklyn, NY 11245, Attention: Prospectus Department
and from Banc of America Securities LLC, Capital Markets (Prospectus
Fulfillment) by e-mail to
email@example.com or by mail to Banc of
America Securities LLC, Capital Markets Operations, 100 West 33rd
Street, 3rd Floor, New York, NY 10001.
A shelf registration statement relating to the securities being
offered has been filed with the Securities and Exchange Commission and
has become effective. This communication shall not constitute an offer
to sell or the solicitation of an offer to buy nor shall there be any
sale of these securities in any state in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the
discovery, development and commercialization of targeted small
molecule drugs to treat life threatening and debilitating diseases.
Our proprietary drug development pipeline is focused on the treatment
of cancer and inflammatory disease and includes clinical candidates
that are designed to regulate therapeutically important targets. In
addition, leading pharmaceutical and biotechnology companies
collaborate with Array to discover and develop drug candidates across
a broad range of therapeutic areas. For more information on Array,
please go to www.arraybiopharma.com.
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including statements about our proposed offering of shares of our
common stock. These statements involve significant risks and
uncertainties, including those discussed in our annual report filed on
form 10-K for the year ended June 30, 2006, our quarterly report on
Form 10-Q and in other reports filed by Array with the Securities and
Exchange Commission. Because these statements reflect our current
expectations concerning future events, our actual results could differ
materially from those anticipated in these forward-looking statements
as a result of many factors. These factors include, but are not
limited to, market conditions and other conditions to the closing of
the proposed offering. We are providing this information as of April
23, 2007. We undertake no duty to update any forward-looking
statements to reflect the occurrence of events or circumstances after
the date of such statements or of anticipated or unanticipated events
that alter any assumptions underlying such statements.
CONTACT: Array BioPharma Inc.
Tricia Haugeto, 303-386-1193
SOURCE: Array BioPharma Inc.